Bullish
Pfizer's TUKYSA regimen approved for front-line HER2+ breast cancer maintenance
Pfizer's TUKYSA regimen has received FDA approval as a front-line maintenance treatment for HER2-positive metastatic breast cancer, potentially expanding its market reach. Additionally, the company declared a $0.43 per share dividend for Q4 2026, marking its 352nd consecutive quarterly dividend.
Key points
- FDA approves TUKYSA regimen for front-line HER2+ breast cancer maintenance.
- Pfizer declares $0.43 per share dividend for Q4 2026.
Sources
AI-generated from public news sources. Not financial advice.
